Promising Potential of Iovance Biotherapeutics’ AMTAGVI: Analyst Recommends Buy Rating Based on Impressive Efficacy and Market Opportunities

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $20.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Iovance Biotherapeutics’ AMTAGVI. The discussions at ASCO ’25 emphasized the impressive long-term efficacy of AMTAGVI, particularly noting a 20% five-year survival rate, which is unprecedented in its treatment setting. The durable off-treatment responses and the enthusiasm from key opinion leaders (KOLs) about having a new option in a setting with limited alternatives further support the positive outlook for AMTAGVI.
Additionally, the updated data from the Phase 2 C-144-01 trial presented at ASCO ’25 reinforced the deep and durable responses of AMTAGVI, with a 31.4% overall response rate and a median duration of response of 36.5 months. The feedback from KOLs also highlighted the need for continued education and expansion of authorized treatment centers to strengthen AMTAGVI’s market position. Despite some challenges, Pantginis believes in the significant market and value-generating potential of AMTAGVI, bolstered by the positive trial results and expert discussions, which increase confidence in Iovance Biotherapeutics’ stock moving forward.

In another report released today, Barclays also maintained a Buy rating on the stock with a $4.00 price target.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IOVA in relation to earlier this year.